Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
Kocheise L, Piseddu I, Vonderlin J, Tjwa ET, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Barciela MR, Gevers TJG, Beretta-Piccoli BT, Londoño MC, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter JP, Fründt TW, Lohse AW, Huber S, von Felden J, Sebode M, Schulze K.
Kocheise L, et al. Among authors: meunier l.
Front Immunol. 2024 Jan 24;15:1369747. doi: 10.3389/fimmu.2024.1369747. eCollection 2024.
Front Immunol. 2024.
PMID: 38327519
Free PMC article.